Paula Tanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paula Tanabe has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Judith A. Paice
5 shared publications- John Joseph Strouse
Department of Medicine, Duke University School of Medicine, Durham, NC
4 shared publications - Allison A. King
Washington University School of Medicine St. Louis Missouri USA
3 shared publications Hayden B. Bosworth
3 shared publications- Judith A. Paice
Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
3 shared publications - Nirmish Shah
Department of Hematology, Duke University School of Medicine, Durham, NC
3 shared publications
Latest Publications
- 23 July 2026
- Published by Elsevier in Pain Management Nursing
- Vol. 27 (6) , e843-e850
Clinician Perspectives of Managing Opioid Related Transitions
- 23 July 2026
- Published by Elsevier in Pain Management Nursing
- Vol. 27 (6) , e843-e850
Clinician Perspectives of Managing Opioid Related Transitions
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Bridging the gap in emergency care for SCD: a call for quality measures and collaborative solutions
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Open AccessBridging the gap in emergency care for SCD: a call for quality measures and collaborative solutions
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
A public health led, statewide approach to improving emergency department care for individuals with sickle cell disease—North Carolina
Sickle cell disease (SCD) is a lifelong condition affecting approximately 100 000 individuals in the United States. It causes progressive organ damage through hemolysis, vaso-occlusion, and chronic inflammation. Patients frequently present to emergency departments (EDs) for acute complications, most commonly severe pain episodes. Unfortunately, acute care encounters are often characterized by negative interactions between patients and providers, fostering mutual distrust and dissatisfaction. In response to community input, the North Carolina Governor’s Council on Sickle Cell Syndrome Medical Research Committee partnered with medical centers, the North Carolina Department of Health, and community-based organizations to implement standardized guidelines for SCD care statewide. Using state-level data, the initiative targeted the 20 ED sites with the highest visit volumes. Each site received an implementation toolbox, developed by the committee and designed to improve emergency care. Following formal outreach, expert consultants engaged site representatives to review the toolbox and initiate discussions on best practices, including Emergency Severity Index (ESI) triage protocols and individualized care plans. Monthly expert consultation (committee members) follow-up calls were established to monitor progress and sustain engagement. Additional efforts were directed toward sites that did not initially respond to formal outreach. To further support the care of patients with complex health care needs who receive care at multiple institutions, we established a multi-institutional monthly virtual patient care conference focused on pain management in high needs patients and sites were invited to participate. This initiative reports a public health program to improve ED care for persons living with SCD.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Open AccessA public health led, statewide approach to improving emergency department care for individuals with sickle cell disease—North Carolina
Sickle cell disease (SCD) is a lifelong condition affecting approximately 100 000 individuals in the United States. It causes progressive organ damage through hemolysis, vaso-occlusion, and chronic inflammation. Patients frequently present to emergency departments (EDs) for acute complications, most commonly severe pain episodes. Unfortunately, acute care encounters are often characterized by negative interactions between patients and providers, fostering mutual distrust and dissatisfaction. In response to community input, the North Carolina Governor’s Council on Sickle Cell Syndrome Medical Research Committee partnered with medical centers, the North Carolina Department of Health, and community-based organizations to implement standardized guidelines for SCD care statewide. Using state-level data, the initiative targeted the 20 ED sites with the highest visit volumes. Each site received an implementation toolbox, developed by the committee and designed to improve emergency care. Following formal outreach, expert consultants engaged site representatives to review the toolbox and initiate discussions on best practices, including Emergency Severity Index (ESI) triage protocols and individualized care plans. Monthly expert consultation (committee members) follow-up calls were established to monitor progress and sustain engagement. Additional efforts were directed toward sites that did not initially respond to formal outreach. To further support the care of patients with complex health care needs who receive care at multiple institutions, we established a multi-institutional monthly virtual patient care conference focused on pain management in high needs patients and sites were invited to participate. This initiative reports a public health program to improve ED care for persons living with SCD.
- Open Access
- 2 June 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (6) , e2513361
Redefining High Emergency Department Utilization for Sickle Cell Disease
Importance: Sickle cell disease (SCD) is a complex hemoglobinopathy. Vaso-occlusive episodes are the primary cause of emergency department (ED) utilization among individuals with SCD. Literature lacks a standardized definition for high ED utilization.Objective: To explore ED utilization, redefine high ED utilization, and describe factors associated with super-high ED utilization among individuals with SCD.Design, Setting, and Participants: This retrospective cohort study analyzed the North Carolina Hospital Discharge Datasets (2013-2019). Participants were included if they had SCD, defined as at least 3 SCD visits (ED, inpatient, or outpatient surgery) in a rolling 5-year period. All age groups, sexes, and payers, regardless of state of residence, were included. Data were analyzed from July 2023 to August 2024.Exposures: Variables included sex, race, ethnicity, age, age at death, distance (in miles) to the closest SCD center, number of annual ED visits, and social vulnerability index (SVI).Main Outcomes and Measures: To determine ED utilization categories, first the distribution of people based on the number of annual ED visits was examined, then the categories across years were identified to determine the data-informed cutoff for each category. Univariate analysis determined differences between participants based on the ED utilization category using χ2 tests of independence or analysis of variance, as applicable. Descriptive statistics were conducted to describe characteristics of utilization in the sample and by ED utilization group. A parsimonious multinomial regression was conducted using significant factors from the univariate analysis.Results: The cohort included 9964 unique patients (5364 [53.83%] female; mean [SD] age, 24.49 [17.54] years), including 9355 Black patients (93.89%), with 100 188 total ED visits from 2013 to 2019. ED visits were categorized into 4 levels: low (0-1 visits per year), moderate (2-9 visits per year), high (10-32 visits per year), and super high (≥33 visits per year). A small subset (178 patients [1.79%]) exhibited super-high ED utilization, contributing disproportionately to the total number of ED visits. Older age, younger age for in-facility deaths, and higher SVI were significantly associated with higher ED utilization. Patients with high utilization were more likely to die, die younger (eg, median [IQR] age at death, 33.0 [30.0-44.0] years in the super-high utilization group vs 50 [38.0-61.0] years in the moderate utilization group), use multiple EDs (eg, 93.8% of participants in the super-high utilization group vs 40.08% of participants in the moderate utilization group), and reside in counties more disadvantaged on socioeconomic and transportation characteristics.Conclusions and Relevance: This cohort study of 7 years of North Carolina Hospital Discharge Data described 4 new categories of ED utilization in SCD. These categories could be used to reframe how high ED use is determined.
- 2 June 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (6) , e2513361
Open AccessRedefining High Emergency Department Utilization for Sickle Cell Disease
Importance: Sickle cell disease (SCD) is a complex hemoglobinopathy. Vaso-occlusive episodes are the primary cause of emergency department (ED) utilization among individuals with SCD. Literature lacks a standardized definition for high ED utilization.Objective: To explore ED utilization, redefine high ED utilization, and describe factors associated with super-high ED utilization among individuals with SCD.Design, Setting, and Participants: This retrospective cohort study analyzed the North Carolina Hospital Discharge Datasets (2013-2019). Participants were included if they had SCD, defined as at least 3 SCD visits (ED, inpatient, or outpatient surgery) in a rolling 5-year period. All age groups, sexes, and payers, regardless of state of residence, were included. Data were analyzed from July 2023 to August 2024.Exposures: Variables included sex, race, ethnicity, age, age at death, distance (in miles) to the closest SCD center, number of annual ED visits, and social vulnerability index (SVI).Main Outcomes and Measures: To determine ED utilization categories, first the distribution of people based on the number of annual ED visits was examined, then the categories across years were identified to determine the data-informed cutoff for each category. Univariate analysis determined differences between participants based on the ED utilization category using χ2 tests of independence or analysis of variance, as applicable. Descriptive statistics were conducted to describe characteristics of utilization in the sample and by ED utilization group. A parsimonious multinomial regression was conducted using significant factors from the univariate analysis.Results: The cohort included 9964 unique patients (5364 [53.83%] female; mean [SD] age, 24.49 [17.54] years), including 9355 Black patients (93.89%), with 100 188 total ED visits from 2013 to 2019. ED visits were categorized into 4 levels: low (0-1 visits per year), moderate (2-9 visits per year), high (10-32 visits per year), and super high (≥33 visits per year). A small subset (178 patients [1.79%]) exhibited super-high ED utilization, contributing disproportionately to the total number of ED visits. Older age, younger age for in-facility deaths, and higher SVI were significantly associated with higher ED utilization. Patients with high utilization were more likely to die, die younger (eg, median [IQR] age at death, 33.0 [30.0-44.0] years in the super-high utilization group vs 50 [38.0-61.0] years in the moderate utilization group), use multiple EDs (eg, 93.8% of participants in the super-high utilization group vs 40.08% of participants in the moderate utilization group), and reside in counties more disadvantaged on socioeconomic and transportation characteristics.Conclusions and Relevance: This cohort study of 7 years of North Carolina Hospital Discharge Data described 4 new categories of ED utilization in SCD. These categories could be used to reframe how high ED use is determined.
- 26 February 2025
- Published by Elsevier in Journal of Emergency Nursing
- Vol. 51 (4) , 626-635
Impact of Individualized Versus Weight-Based Pain Protocols on Patient Satisfaction for Patients With Sickle Cell Disease Experiencing a Vaso-Occlusive Episode
- 26 February 2025
- Published by Elsevier in Journal of Emergency Nursing
- Vol. 51 (4) , 626-635
Impact of Individualized Versus Weight-Based Pain Protocols on Patient Satisfaction for Patients With Sickle Cell Disease Experiencing a Vaso-Occlusive Episode
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Adherence to and factors associated with hydroxyurea use in children ages 2 to 16 years old with sickle cell disease in North Carolina
Objectives: Hydroxyurea (HU) is a disease modifying therapy approved for use in children 9 months and older with sickle cell anemia for stroke prevention; however, HU adherence continues to be low. We examined sociodemographic characteristics and HU adherence for 2 cohorts, 12-month Medicaid cohort versus 24-month Medicaid cohort. The study objective was to determine if longer continuous Medicaid enrollment was associated with better HU adherence. Methods: Retrospective cohort study of HU adherence among children 2-16 years with SCD enrolled in NC Medicaid. Adherence assessed using HU Proportion of Days Covered (PDC), the sum of HU prescription fill days divided by the number of Medicaid days. Adherence was good if HU PDC was ≥80%, moderate 60%-79%, and poor <60%. Chi-square was used to determine differences in HU adherence between cohorts (12-month versus 24-month), and to identify any correlations of HU PDC with sociodemographic characteristics and predictor variables. Results: The 12-month cohort, only 15% had Good/Moderate HU adherence while 85% had Poor HU adherence. The 24-month cohort had 25% of the participants with Good/Moderate HU adherence while 75% had Poor HU adherence. Overall, the 24-month cohort had higher HU adherence compared to the 12-month cohort (25% versus 15%, P = .0001). Of those children in the 24-month cohort with Good/Moderate HU adherence, 56% were school-aged and 26% were preschoolers as compared to those with Poor HU adherence as 41% were school-aged and 32% were adolescents (P = .0007). Conclusion: HU adherence was low in children with SCD, though better for younger children with longer Medicaid enrollment.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Open AccessAdherence to and factors associated with hydroxyurea use in children ages 2 to 16 years old with sickle cell disease in North Carolina
Objectives: Hydroxyurea (HU) is a disease modifying therapy approved for use in children 9 months and older with sickle cell anemia for stroke prevention; however, HU adherence continues to be low. We examined sociodemographic characteristics and HU adherence for 2 cohorts, 12-month Medicaid cohort versus 24-month Medicaid cohort. The study objective was to determine if longer continuous Medicaid enrollment was associated with better HU adherence. Methods: Retrospective cohort study of HU adherence among children 2-16 years with SCD enrolled in NC Medicaid. Adherence assessed using HU Proportion of Days Covered (PDC), the sum of HU prescription fill days divided by the number of Medicaid days. Adherence was good if HU PDC was ≥80%, moderate 60%-79%, and poor <60%. Chi-square was used to determine differences in HU adherence between cohorts (12-month versus 24-month), and to identify any correlations of HU PDC with sociodemographic characteristics and predictor variables. Results: The 12-month cohort, only 15% had Good/Moderate HU adherence while 85% had Poor HU adherence. The 24-month cohort had 25% of the participants with Good/Moderate HU adherence while 75% had Poor HU adherence. Overall, the 24-month cohort had higher HU adherence compared to the 12-month cohort (25% versus 15%, P = .0001). Of those children in the 24-month cohort with Good/Moderate HU adherence, 56% were school-aged and 26% were preschoolers as compared to those with Poor HU adherence as 41% were school-aged and 32% were adolescents (P = .0007). Conclusion: HU adherence was low in children with SCD, though better for younger children with longer Medicaid enrollment.
- 23 October 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 144-148
Emergency department intravenous fluid resuscitation and renal outcomes among adults with sickle cell disease
- 23 October 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 144-148
Emergency department intravenous fluid resuscitation and renal outcomes among adults with sickle cell disease
- 12 November 2023
- Published by Wiley in Academic Emergency Medicine
- Vol. 30 (12) , 1210-1222
A comparison of the effect of patient‐specific versus weight‐based protocols to treat vaso‐occlusive episodes in the emergency department
Background: Vaso‐occlusive crises (VOCs) cause debilitating pain and are a common cause of emergency department (ED) visits, for people with sickle cell disease (SCD). Strategies for achieving optimal pain control vary widely despite evidence‐based guidelines. We tested existing guidelines and hypothesized that a patient‐specific pain protocol (PSP) written by their SCD provider may be more effective than weight‐based (WB) dosing of parenteral opiate medication, in relieving pain.Methods: This study was a prospective, randomized controlled trial comparing a PSP versus WB protocol for patients presenting with VOCs to six EDs. Patients were randomized to a PSP or WB protocol prior to an ED visit. The SCD provider wrote their protocol and placed it in the electronic health record for future ED visits with VOC exclusion criteria that included preexisting PSP excluding parenteral opioid analgesia or outpatient use of buprenorphine or methadone or highly suspected for COVID‐19. Pain intensity scores, side effects, and safety were obtained every 30 min for up to 6 h post–ED bed placement. The primary outcome was change in pain intensity score from placement in an ED space to disposition or 6 h.Results: A total of 328 subjects were randomized; 104 participants enrolled (ED visit, target n = 230) with complete data for 96 visits. The study was unable to reach the target sample size and stopped early due to the impact of COVID‐19. We found no significant differences between groups in the primary outcome; patients randomized to a PSP had a shorter ED length of stay (p = 0.008), and the prevalence of side effects was low in both groups. Subjects in both groups experienced both a clinically meaningful and a statistically significant decrease in pain (27 mm on a 0‐ to 100‐mm scale).Conclusions: We found a shorter ED length of stay for patients assigned to a PSP. Patients in both groups experienced good pain relief without significant side effects.
- 12 November 2023
- Published by Wiley in Academic Emergency Medicine
- Vol. 30 (12) , 1210-1222
A comparison of the effect of patient‐specific versus weight‐based protocols to treat vaso‐occlusive episodes in the emergency department
Background: Vaso‐occlusive crises (VOCs) cause debilitating pain and are a common cause of emergency department (ED) visits, for people with sickle cell disease (SCD). Strategies for achieving optimal pain control vary widely despite evidence‐based guidelines. We tested existing guidelines and hypothesized that a patient‐specific pain protocol (PSP) written by their SCD provider may be more effective than weight‐based (WB) dosing of parenteral opiate medication, in relieving pain.Methods: This study was a prospective, randomized controlled trial comparing a PSP versus WB protocol for patients presenting with VOCs to six EDs. Patients were randomized to a PSP or WB protocol prior to an ED visit. The SCD provider wrote their protocol and placed it in the electronic health record for future ED visits with VOC exclusion criteria that included preexisting PSP excluding parenteral opioid analgesia or outpatient use of buprenorphine or methadone or highly suspected for COVID‐19. Pain intensity scores, side effects, and safety were obtained every 30 min for up to 6 h post–ED bed placement. The primary outcome was change in pain intensity score from placement in an ED space to disposition or 6 h.Results: A total of 328 subjects were randomized; 104 participants enrolled (ED visit, target n = 230) with complete data for 96 visits. The study was unable to reach the target sample size and stopped early due to the impact of COVID‐19. We found no significant differences between groups in the primary outcome; patients randomized to a PSP had a shorter ED length of stay (p = 0.008), and the prevalence of side effects was low in both groups. Subjects in both groups experienced both a clinically meaningful and a statistically significant decrease in pain (27 mm on a 0‐ to 100‐mm scale).Conclusions: We found a shorter ED length of stay for patients assigned to a PSP. Patients in both groups experienced good pain relief without significant side effects.
- 5 January 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (5) , 518-526
Time to pain relief: A randomized controlled trial in the emergency department during vaso‐occlusive episodes in sickle cell disease
Objective: Compare time to pain relief (minimum of a 13 mm and 30% reduction) during an Emergency Department (ED) visit among patients with sickle cell disease (SCD) experiencing severe pain associated with a vaso‐occlusive episode who were randomized to receive either an individualized or weight‐based pain protocol.Methods: A randomized controlled trial in two EDs. Adults with sickle cell disease. Research staff recorded pain scores every 30 min during an ED visit (up to 6 h in the ED) using a 0–100 mm visual analogue scale. Analysis included 122 visits, representing 49 patients (individualized: 61 visits, 25 patients; standard: 61 visits, 24 patients).Results: Pain reduction across 6‐h was greater for the individualized compared to the standard protocol (protocol‐by‐time: p = .02; 6‐h adjusted pain score comparison: Individualized: M = 29.2, SD = 38.8, standard: M = 45.3, SD = 35.6; p = .03, Cohen d = 0.43). Hazards models indicated a greater probability of 13 mm (HR = 1.54, 95% CI = 1.05, 2.27, p = .03) and 30% (HR = 1.71, 95% CI = 1.11, 2.63, p = .01) reduction in the individualized relative to the standard protocol.Conclusions: Patients who received treatment with an individualized protocol experienced a more rapid reduction in pain, including a 13 mm and 30% reduction in pain scores when compared to those that received weight‐based dosing.
- 5 January 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (5) , 518-526
Time to pain relief: A randomized controlled trial in the emergency department during vaso‐occlusive episodes in sickle cell disease
Objective: Compare time to pain relief (minimum of a 13 mm and 30% reduction) during an Emergency Department (ED) visit among patients with sickle cell disease (SCD) experiencing severe pain associated with a vaso‐occlusive episode who were randomized to receive either an individualized or weight‐based pain protocol.Methods: A randomized controlled trial in two EDs. Adults with sickle cell disease. Research staff recorded pain scores every 30 min during an ED visit (up to 6 h in the ED) using a 0–100 mm visual analogue scale. Analysis included 122 visits, representing 49 patients (individualized: 61 visits, 25 patients; standard: 61 visits, 24 patients).Results: Pain reduction across 6‐h was greater for the individualized compared to the standard protocol (protocol‐by‐time: p = .02; 6‐h adjusted pain score comparison: Individualized: M = 29.2, SD = 38.8, standard: M = 45.3, SD = 35.6; p = .03, Cohen d = 0.43). Hazards models indicated a greater probability of 13 mm (HR = 1.54, 95% CI = 1.05, 2.27, p = .03) and 30% (HR = 1.71, 95% CI = 1.11, 2.63, p = .01) reduction in the individualized relative to the standard protocol.Conclusions: Patients who received treatment with an individualized protocol experienced a more rapid reduction in pain, including a 13 mm and 30% reduction in pain scores when compared to those that received weight‐based dosing.